SeekingAlpha · Aug 13, 2026
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research Symposium - Slideshow
2026-08-13. The following slide deck was published by MiNK Therapeutics, Inc.
IN
NASDAQ · INKT
MiNK Therapeutics, Inc.
Healthcare · Biotechnology
$12.11
Down-$0.07 (-0.57%)
Updated Sep 29, 2026, 12:13 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 58.3M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $8.48 – $16.93
- Volume
- 13.75K
- Avg. volume
- 28.08K
Price performance · INKT
INKT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
INKT closed at $12.11 after 20 trading sessions, up 9.20% for the selected period.
- Last close
- $12.11
- Period change
- +9.20%
- Period low
- $10.95
- Period high
- $12.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $11.82 | $12.44 | $11.715 | $12.11 | 13.75K |
| Sep 25, 2026 | $12.00 | $12.46 | $11.70 | $12.18 | 11.49K |
| Sep 24, 2026 | $12.36 | $12.42 | $11.7461 | $12.30 | 9.98K |
| Sep 23, 2026 | $12.50 | $12.50 | $11.6801 | $12.35 | 14.81K |
| Sep 22, 2026 | $12.14 | $12.3799 | $11.5006 | $12.11 | 8.58K |
| Sep 21, 2026 | $11.835 | $12.69 | $11.5663 | $12.25 | 8.03K |
| Sep 18, 2026 | $12.00 | $12.0842 | $11.70 | $12.05 | 18.91K |
| Sep 17, 2026 | $11.5799 | $12.00 | $11.4705 | $11.71 | 4.05K |
| Sep 16, 2026 | $11.47 | $11.6812 | $11.3064 | $11.59 | 4.8K |
| Sep 15, 2026 | $11.70 | $11.70 | $11.40 | $11.41 | 15.77K |
| Sep 14, 2026 | $12.25 | $12.405 | $11.75 | $11.97 | 55.93K |
| Sep 11, 2026 | $12.17 | $12.475 | $11.90 | $12.00 | 42.35K |
| Sep 10, 2026 | $12.6899 | $12.6899 | $12.00 | $12.13 | 22.43K |
| Sep 9, 2026 | $11.535 | $12.1549 | $11.535 | $11.90 | 16.97K |
| Sep 8, 2026 | $11.61 | $11.85 | $11.45 | $11.45 | 11.02K |
| Sep 4, 2026 | $11.16 | $11.64 | $11.16 | $11.64 | 5.87K |
| Sep 3, 2026 | $11.08 | $11.54 | $11.08 | $11.23 | 3.21K |
| Sep 2, 2026 | $11.00 | $11.42 | $10.82 | $11.33 | 8.26K |
| Sep 1, 2026 | $11.02 | $11.35 | $10.95 | $10.95 | 2.24K |
| Aug 31, 2026 | $11.51 | $11.75 | $10.95 | $11.09 | 11.88K |
Latest INKT news
The latest Smart Investors Daily articles mentioning INKT.
Stock researchCompany · Overview
INKT research
Overview
Company profile and research snapshot.
Company profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | HC Wainwright & Co. | Neutral | — |
| Jul 14, 2025 | William Blair | Market Perform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 13, 2026
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsJennifer Buell - Co-Founder, President, CEO &...
Benzinga · Aug 13, 2026
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Benzinga · Aug 13, 2026
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
